Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Don W. Shaffer"'
Autor:
Mario von Depka, Bernard Boneu, Johan Frieling, Marie Helene Horellou, R. Campbell Tait, Don W. Shaffer, Laura J. Bonfiglio, Robert Klamroth, Carl-Erik Dempfle, Andreas Tiede, John Lazarchick, Andrew D Mumford, C. Shiach, Jacqueline Conard, Francesco Baudo, Sam Schulman
Publikováno v:
Thrombosis and Haemostasis. 99:616-622
SummaryDuring surgery and childbirth, patients with hereditary antithrombin (AT) deficiency are at high risk for thrombosis,and heparin prophylaxis may not be sufficiently efficacious. In these patients, exogenous AT may be used in association with h
Autor:
Van L. Lackey, F. Anthony Greco, John D. Hainsworth, Don W. Shaffer, Manuel Grimaldi, Sharlene Litchy
Publikováno v:
Journal of Clinical Oncology. 23:1088-1095
Purpose To compare the benefit of maintenance rituximab therapy versus rituximab re-treatment at progression in patients with previously treated indolent non-Hodgkin's lymphoma. Patients and Methods Between June 1998 and August 2002, 114 patients who
Autor:
Sharlene Litchy, John D. Hainsworth, J. R. Gray, F. Anthony Greco, Gerry Ann Houston, James D. Bearden, Don W. Shaffer
Publikováno v:
Clinical Lung Cancer. 6:33-42
This study was designed to evaluate the efficacy and toxicity of a novel preoperative combined-modality regimen in patients with locally advanced non-small-cell lung cancer (NSCLC). Patients with clinical stage IIB, IIIA, or IIIB NSCLC received preop
Autor:
J R Eckardt, David Rinaldi, C DeMoor, C. D. Stephens, D. D. Von Hoff, G. I. Rodriguez, Geoffrey R. Weiss, Don W. Shaffer
Publikováno v:
Anti-Cancer Drugs. 7:402-409
The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare t
Autor:
F. Anthony Greco, Lisa H. Morrissey, Denise A. Yardley, John D. Hainsworth, Gladys Rodriguez, Joan B. Erland, Howard A. Burris, Don W. Shaffer, Sharlene Litchy, Robert C. Hermann
Publikováno v:
The oncologist. 9(6)
Purpose. To evaluate the efficacy and toxicity of the sequential administration of paclitaxel (Taxol®; Bristol-Myers Squibb; Princeton, NJ), carboplatin (Paraplatin®; Bristol-Myers Squibb), and oral etoposide (VePesid®; Bristol-Myers Squibb) follo
Autor:
J. R. Gray, J. Lucian Davis, M. Thomas, David Rinaldi, Don W. Shaffer, Valerie M. Sutton, John D. Hainsworth, A. A. Meluch, Kathleen Yost, L A Kalman, F. Anthony Greco
Publikováno v:
Cancer journal (Sudbury, Mass.). 9(4)
Purpose This phase II study was designed to determine the feasibility, toxicity, and therapeutic efficacy of a novel outpatient combined-modality preoperative regimen in patients with localized esophageal cancer. Patients and methods One hundred twen
Autor:
Don W. Shaffer, Burris Ha rd, Baker M, F A Greco, John D. Hainsworth, Joan B. Erland, Daniel C. Scullin
Publikováno v:
Cancer investigation. 21(2)
The purpose of the study was to evaluate the combination of gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer. Between March 1998 and February 1999, 30 patients with relapsed or refractory sma
Publikováno v:
Diagnostic cytopathology. 9(5)
A case of multiple myeloma diagnosed by fine-needle aspiration (FNA) biopsy and confirmed by laboratory studies in a patient with a history of renal-cell carcinoma is presented. The patient was diagnosed with renal-cell carcinoma of the right kidney
Autor:
J R Eckardt, Lon Smith, Don W. Shaffer, S. Fields, Gladys Rodriguez, Howard A. Burris, S. Kalter, J. G. Kuhn, Geoffrey R. Weiss, Rebecca Irvin
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 11(5)
PURPOSE To determine the potential efficacy and dose-limiting toxicity of taxotere, a hemisynthetic inhibitor of tubulin depolymerization. PATIENTS AND METHODS Fifty-eight patients were administered taxotere in this phase I clinical trial as a 6-hour
Autor:
Johan Frieling, Don W. Shaffer, Francesco Baudo, Mario von Depka, C. Shiach, Judith Bonfiglio
Publikováno v:
Blood. 104:4076-4076
Congenital antithrombin (AT) deficiency is a major cause of thrombophilia. Prophylactic AT replacement in high risk situations may be considered for these patients as AT deficiency may lead to insufficient anticoagulation resulting in acute deep veno